Literature DB >> 9146791

Reinfection versus recrudescence in Helicobacter pylori infection.

A van der Ende1, R W van der Hulst, J Dankert, G N Tytgat.   

Abstract

Antimicrobial treatment of Helicobacter pylori is the proper management strategy in patients with ulcers. A high rate of H. pylori reinfection after successful eradication therapy however, may give rise to ulcer recurrence. The risk of reinfection, depending on the prevalence and the rate of acquisition of H. pylori infection, varies with socioeconomic status, age and geographical location. The rate of reinfection may vary in a similar way. The available data in the literature reveal that reinfection by H. pylori is low or absent in developed countries and may be lower than the initial rate of acquisition. In addition, reported cases of H. pylori reinfection are often cases of recrudescent H. pylori infection. Acquisition rate in developing countries is high, so the reinfection rate is expected to be higher than in developed countries. However, studies discriminating reinfection from recrudescence are lacking and therefore more data from developing regions are needed to settle if 'cured once, cured forever' holds true.

Entities:  

Mesh:

Year:  1997        PMID: 9146791     DOI: 10.1046/j.1365-2036.11.s1.10.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  3 in total

1.  cagA-positive Helicobacter pylori populations in China and The Netherlands are distinct.

Authors:  A van der Ende; Z J Pan; A Bart; R W van der Hulst; M Feller; S D Xiao; G N Tytgat; J Dankert
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

2.  Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations.

Authors:  Jennifer M Taylor; Melanie E Ziman; Julie Fong; Jay V Solnick; Michael Vajdy
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

3.  Helicobacter pylori Recurrence after Eradication Therapy in Jiangjin District, Chongqing, China.

Authors:  Gang Zhou
Journal:  Gastroenterol Res Pract       Date:  2020-04-06       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.